سعر ازاتريباكت 200 مجم / 5 مل معلق22.5مل 2022

Azatribact oral suspension containing azithromycin 200 mg per 5 ml (22.5 ml bottle), a macrolide (azalide) antibiotic marketed in Egypt by Riva Pharma.

• Acute bacterial sinusitis, acute bacterial otitis media, community-acquired pneumonia and acute bacterial skin and skin structure infectionsPopulation: Children aged 6 months and older weighing less than 45 kgelectronic medicines compendium (eMC)
• Acute streptococcal tonsillitis and pharyngitisPopulation: Children aged 2 years and older weighing less than 45 kgelectronic medicines compendium (eMC)
• Additionally urethritis/cervicitis due to Chlamydia trachomatis or (with another agent, e.g. ceftriaxone) Neisseria gonorrhoeae; acute exacerbation of chronic bronchitis (adults only)Population: Adults and adolescents of at least 45 kg unable to swallow solid formselectronic medicines compendium (eMC)

• Most common: diarrhoea, headache, vomiting, abdominal pain, nausea and abnormal laboratory values. Important: anaphylaxis, torsades de pointes and ventricular arrhythmias, pseudomembranous colitis, hepatic failure, severe cutaneous reactions; hearing impairment (deafness, tinnitus) and myasthenia gravis reported.International label, same formulation · electronic medicines compendium (eMC)

• Hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic, or any excipient.International label, same formulation · electronic medicines compendium (eMC)

• Serious hypersensitivity and severe cutaneous adverse reactions (angioedema, anaphylaxis, SJS, TEN, DRESS, AGEP) may occur; stop treatment and manage appropriately; reactions may recur.International label, same formulation · electronic medicines compendium (eMC)
• QT prolongation and torsades de pointes: use with caution in congenital or documented QT prolongation, with other QT-prolonging drugs, electrolyte disturbance (hypokalaemia, hypomagnesaemia), clinically relevant bradycardia, arrhythmia or severe heart failure, and in elderly patients.International label, same formulation · electronic medicines compendium (eMC)
• Hepatotoxicity: caution in significant hepatic disease; fulminant hepatitis leading to liver failure reported; stop if signs of hepatitis occur.International label, same formulation · electronic medicines compendium (eMC)

• QT-prolonging drugs (class IA and III antiarrhythmics, cisapride, terfenadine, antipsychotics such as pimozide, antidepressants such as citalopram, fluoroquinolones)Additive risk of QT prolongation and ventricular arrhythmia; use with caution.electronic medicines compendium (eMC)
• Statins (e.g. atorvastatin)Post-marketing cases of rhabdomyolysis with concomitant use; caution.electronic medicines compendium (eMC)
• CiclosporinCmax increased by about 24%; clinical and therapeutic drug monitoring, adjust ciclosporin dose if required.electronic medicines compendium (eMC)

• Observational data from more than 7000 exposed pregnancies mostly do not suggest an increased risk of major malformations; evidence on miscarriage is inconclusive; use in pregnancy only if clinically needed.International label, same formulation · electronic medicines compendium (eMC)
• Published literature and postmarketing experience over several decades have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Excreted in human milk to a substantial extent; no serious effects observed in breastfed infants but diarrhoea, fungal mucosal infection and sensitisation are possible; decide on breastfeeding versus therapy.International label, same formulation · electronic medicines compendium (eMC)

• Azithromycin: Macrolide antibacterial; binds the 50S ribosomal subunit and inhibits bacterial protein synthesis (Zithromax USPI 12.1/12.4).